| Trial ID # | NCT05194072 |
| Phase | I |
| Drug Class | Antibody Drug Conjugates: B7H4 |
| Drug Name | Felmetatug vedotin |
| Alternate Drug Names | SGN-B7H4V |
| Drugs in Trial | Felmetatug vedotin |
| Eligible Participant | Advanced solid tumors |
| Patients Enrolled | 86 patients in dose escalation; median 3 prior therapies (1-17), 21 OC |
| Efficacy | ORR: 20% (4PR, n=20) |
| Reference | Perez CA et al. First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001). Ann Oncol (2023) 34(2) abstract 660MO |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.